OBJECTIVE: To evaluate the effects of the pacemaker funny current (I(f)) inhibitor ivabradine on heart rate (HR), left ventricular (LV) systolic and diastolic function, and left atrial performance in healthy cats and cats with hypertrophic cardiomyopathy (HCM). ANIMALS: 6 healthy cats and 6 cats with subclinical HCM. PROCEDURES: Anesthetized cats underwent cardiac catheterization and were studied over a range of hemodynamic states induced by treatment with esmolol (200 to 400 μg/kg/min, IV), esmolol and dobutamine (5 μg/kg/min, IV), ivabradine (0.3 mg/kg, IV), and ivabradine and dobutamine. Left ventricular systolic and diastolic function, cardiac output, and left atrial function were studied via catheter-based methods and echocardiography. RESULTS: Treatment with ivabradine resulted in a significant reduction of HR, rate-pressure product, and LV contractile function and a significant increase in LV end-diastolic pressure, LV end-diastolic wall stress, and LV relaxation time constant (tau) in cats with HCM. Concurrent administration of ivabradine and dobutamine resulted in a significant increase of LV contractility and lusitropy, with blunted chronotropic effects of the catecholamine. Left atrial performance was not significantly altered by ivabradine in cats with HCM. Regression analysis revealed an association between maximum rate of LV pressure rise and tau in cats with HCM. CONCLUSIONS AND CLINICAL RELEVANCE: Ivabradine had significant effects on several cardiovascular variables in anesthetized cats with HCM. Studies in awake cats with HCM are needed to clinically validate these findings.
OBJECTIVE: To evaluate the effects of the pacemaker funny current (I(f)) inhibitor ivabradine on heart rate (HR), left ventricular (LV) systolic and diastolic function, and left atrial performance in healthy cats and cats with hypertrophic cardiomyopathy (HCM). ANIMALS: 6 healthy cats and 6 cats with subclinical HCM. PROCEDURES: Anesthetized cats underwent cardiac catheterization and were studied over a range of hemodynamic states induced by treatment with esmolol (200 to 400 μg/kg/min, IV), esmolol and dobutamine (5 μg/kg/min, IV), ivabradine (0.3 mg/kg, IV), and ivabradine and dobutamine. Left ventricular systolic and diastolic function, cardiac output, and left atrial function were studied via catheter-based methods and echocardiography. RESULTS: Treatment with ivabradine resulted in a significant reduction of HR, rate-pressure product, and LV contractile function and a significant increase in LV end-diastolic pressure, LV end-diastolic wall stress, and LV relaxation time constant (tau) in cats with HCM. Concurrent administration of ivabradine and dobutamine resulted in a significant increase of LV contractility and lusitropy, with blunted chronotropic effects of the catecholamine. Left atrial performance was not significantly altered by ivabradine in cats with HCM. Regression analysis revealed an association between maximum rate of LV pressure rise and tau in cats with HCM. CONCLUSIONS AND CLINICAL RELEVANCE: Ivabradine had significant effects on several cardiovascular variables in anesthetized cats with HCM. Studies in awake cats with HCM are needed to clinically validate these findings.
Authors: Richard E Cober; Karsten E Schober; Tony C A Buffington; Xiaobai Li; Sabine C Riesen; John D Bonagura Journal: J Vet Cardiol Date: 2011-10-24 Impact factor: 1.701
Authors: Andrew A Gibb; Emma K Murray; Deborah M Eaton; Anh T Huynh; Dhanendra Tomar; Joanne F Garbincius; Devin W Kolmetzky; Remus M Berretta; Markus Wallner; Steven R Houser; John W Elrod Journal: JACC Basic Transl Sci Date: 2021-08-23
Authors: Markus Wallner; Deborah M Eaton; Remus M Berretta; Laura Liesinger; Matthias Schittmayer; Juergen Gindlhuber; Jichuan Wu; Mark Y Jeong; Ying H Lin; Giulia Borghetti; Sandy T Baker; Huaqing Zhao; Jessica Pfleger; Sandra Blass; Peter P Rainer; Dirk von Lewinski; Heiko Bugger; Sadia Mohsin; Wolfgang F Graier; Andreas Zirlik; Timothy A McKinsey; Ruth Birner-Gruenberger; Marla R Wolfson; Steven R Houser Journal: Sci Transl Med Date: 2020-01-08 Impact factor: 19.319
Authors: Michelle N Rohrbaugh; Karsten E Schober; Jaylyn D Rhinehart; John D Bonagura; Amy Habing; Vedat Yildiz Journal: J Vet Intern Med Date: 2020-05-04 Impact factor: 3.333
Authors: Ge Li-Sha; Liu Li; Zhou De-Pu; Shi Zhe-Wei; Gu Xiaohong; Chen Guang-Yi; Li Jia; Lin Jia-Feng; Chu Maoping; Li Yue-Chun Journal: Front Pharmacol Date: 2018-03-05 Impact factor: 5.810